-transparent.png){kind=logo}
HR 756 is a new cephalosporin derivative suitable for parenteral use. The compound possesses an unusally broad spectrum of antibacterial activity especially against gram-negative bacteria. Besides Escherichia coli, Salmonella, Klebsiella, indole-negative Proteae and other species also indol-positive Proteae, Serratia marcescens, Enterobacter and many Pseudomonas aeruginosa strains are inhibited by this compound. HR 756 is stable to most of the beta-lactamases produced by gram-negative organisms. Tests on different infection models also provided evidence of the high efficacy of HR 756 in vivo.
Related Publications
R Heymès, and
A Lutz, and
E Schrinner
January 1977,
Antimicrobial agents and chemotherapy,
R Heymès, and
A Lutz, and
E Schrinner
April 1976,
The Journal of antibiotics,
R Heymès, and
A Lutz, and
E Schrinner
February 1979,
Die Medizinische Welt,
R Heymès, and
A Lutz, and
E Schrinner
January 1965,
Antimicrobial agents and chemotherapy,
R Heymès, and
A Lutz, and
E Schrinner
June 1970,
The Medical journal of Australia,
R Heymès, and
A Lutz, and
E Schrinner
January 1979,
Chinese medical journal,
R Heymès, and
A Lutz, and
E Schrinner
July 1976,
Antimicrobial agents and chemotherapy,
R Heymès, and
A Lutz, and
E Schrinner
February 1974,
The American journal of the medical sciences,
R Heymès, and
A Lutz, and
E Schrinner
January 1975,
Chemotherapy,
R Heymès, and
A Lutz, and
E Schrinner
January 1966,
Problemy tuberkuleza,
